ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Art Przybyl use to state that EBITDA growth was he best to measure a company like ANIP which is growing rapidly organically and through acquisitions.

Q3 2016 Adjusted non-GAAP EBITDA was $16.354 Million
Q4 2016 Adjusted non-GAAP EBITDA was $17.933 Million

A 9.66% increase over Q3.

The fact they are changing their accounting methods is to set themselves up for being compared to their peers. Not so much now, but as they grow significantly over the next couple of years.


JMHO.